The results of a phase II clinical trial (NCT00501592) showed that Obeticholic Acid significantly improved insulin sensitivity in patients with T2DM complicated with NAFLD, significantly improved hepatic fibrosis, and liver enzymology indexes (p < 0.05). The gene discussed is INS; the disease is Hepatic fibrosis.